Biotech GAiners: BioCryst Pharmaceuticals (NASDAQ:BCRX), Dyax Corp. (NASDAQ:DYAX), Novavax, Inc. (NASDAQ:NVAX), Merrimack Pharmaceuticals Inc (NASDAQ:MACK)

Gilead Sciences GILD NASDAQ:GILD

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) shares closed up nearly 11% on Tuesday after the company reported positive data from its OPuS-1 mid-stage study involving BCX4161 as a treatment for hereditary angioedema, or HAE. This is a rare immune disorder that can cause swelling of the face, breathing airways, and also causes abdominal cramping. According to the preliminary results from the company’s proof-of-concept study, BCX4161 met both the primary and secondary endpoints. BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) stock performance was 10.94% in last session and finished the day at $9.99. Traded volume was 7.84million shares in the last session and the average volume of the stock remained 896.58K shares. The beta of the stock remained 2.69. BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) insider ownership is 2.00%.

Dyax Corp. (NASDAQ:DYAX)‘s stock had its “buy” rating restated by investment analysts at BofA Merrill Lynch in a note issued to investors on Friday, 09 May 2014, Stock Ratings Network reports. Dyax Corp. (NASDAQ:DYAX) rose 27.42 percent to $8.41 Tuesday on volume of 6.39million shares. The intra-day range of the stock was $6.69 to $8.48. Dyax Corp. (NASDAQ:DYAX) has a market capitalization of $1.14billion.

Novavax, Inc. (NASDAQ:NVAX) gained 10.36% on 20 May 2014, recently the company declared follow-up data from its dose-ranging Phase 1 clinical trial of its respiratory syncytial virus (RSV) F-protein vaccine in 220 elderly adults (60 years of age and older, with a mean age of 68) that was initiated in October 2012. In the placebo-controlled trial, subjects received a single injection of either 60ug or 90ug of the RSV F-protein vaccine applicant, with or without aluminum phosphate as an adjuvant. On Tuesday, shares of Novavax, Inc. (NASDAQ:NVAX) advanced 5.77% to close the day at $5.13. Company return on investment (ROI) is -25.50% and its monthly performance is recorded as 31.88%. Novavax, Inc. (NASDAQ:NVAX) quarterly revenue growth is -15.62%.

Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK), after the big top and breakaway gap a few weeks ago, it coiled very tightly and quietly, and suddenly picked up. It’s been up four days in a row, and on Tuesday, it took out the May 1st 7.65 line, up 48 cents, or 6.38%, on 2.6 million shares, closing at 8.00. It’s a beautiful chart. Looking for something around 11ish. Merrimack Pharmaceuticals Inc (NASDAQ:MACK) stock performance was 6.38% in last session and finished the day at $8.00. Traded volume was 2.69million shares in the last session and the average volume of the stock remained 2.12million shares. Merrimack Pharmaceuticals Inc (NASDAQ:MACK) insider ownership is 5.40%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone